Immuneering Corporation

IMRX Healthcare Biotechnology

Immuneering Corporation’s revenue for fiscal 2022 (year ended December 2022) was $317,000.00. In the quarter to June 2026, EPS grew 32.5% and free cash flow fell 74.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.59 0.05 −1.37%
Market cap
$235.5M
P/E
0.0×
Fwd P/E
−3.5×
Dividend yield
—
F-score
3/9
Altman Z
4.47
Beneish M
−6.35
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
24.00 17.50 32.45 19.47
Net Debt/EBITDA
14.96 12.58 10.07 7.73
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.30) (0.23) (0.29) (0.26)
Book value per Share
5.75 4.96 3.19 2.95
Free Cash Flow
(11.98) (9.96) (18.51) (16.53)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates